Kristin Stafford
Executive VP & CFOMs. Kristin Stafford, C.P.A., has been a Director of Theravance Biopharma Inc. since September 23, 2026. She is Executive Vice President & Chief Financial Officer of Zymeworks Inc. from April 1, 2026. Ms. Stafford served as Senior Vice President, Chief Accounting Officer at Royalty Pharma plc since December 2018. She served as Chief Accounting Officer at RP Management, LLC. Ms. Stafford serves as Independent Directors at NovoCure Limited since March 2023. She served as Vice President, Finance of Royalty Pharma and Chief Financial Officer of BioPharma Credit plc, an affiliate of Royal Pharma, from 2016 to 2018. Previously, Ms. Stafford was a Director at Ernst & Young LLP Capital Markets in London, specializing in US transactions involving European life sciences companies. Ms. Stafford also previously managed the external SEC reporting for iHeartMedia and was an Auditor at Deloitte. Ms. Stafford is a Certified Public Accountant. She is a CPA and holds a Bachelor of Science degree in Business Administration from Sonoma State University.
Positions
- Company NameZymeworks Inc.Stock CodeZYMEPositionExecutive VP & CFOColleagues
- KHKenneth H. GalbraithChairman of the Board, CEO & President
- PAPaul A. MooreChief Scientific Officer
- SPScott PlatshonExecutive VP & Chief Business Officer
- MHMark HollywoodExecutive VP & COO
- SMSusan M. MahonyLead Independent Director
- CECarlos E. CampoyIndependent Director
- GAGregory Austin CiongoliIndependent Director
- KMKelvin M. NeuIndependent Director
